The Lancet Conference Alerts | Read our late-breaking content from ESC Congress 2025 ++++++

Benefit–harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials Free to access with registration until Sept 9, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01391-1/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc25&_hsenc=p2ANqtz-_0rdWX13DoIC8P5Gs_325guJHC3Jfrx8OH3NhwWsQx96_yMVzjY9ebPfcA0IzCp0hDcXkwNFDrCS_lGSLP8i22bhq_Bw&_hsmi=378460064&utm_content=378460064&utm_source=hs_email Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial Free to access with registration until Sept 9, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01585-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc25&_hsenc=p2ANqtz-_gYeCW3HFAIMyS29svYePIdsztMHN_3ganmRsWYt0PHmNLZ7ZU-3QVuAEO91LJlr0cHKkAnV9PaKRLTFCjAbpi3Mpz9A&_hsmi=378460064&utm_content=378460064&utm_source=hs_email Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial Free to access with registration until Sept 9, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01584-3/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc25&_hsenc=p2ANqtz-_7X7YxUp_zLmzcDv7QmM4vQ1KkST_MPvUI-rZ-TUMr3RS7h70IU-HlYahC-Qm4zy9muawp-SUMfCdE1CyxoBM7vrqHow&_hsmi=378460064&utm_content=378460064&utm_source=hs_email Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION–STEMI): a multicentre, non-inferiority, open-label, randomised trial Free to access with registration until Sept 9, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01529-6/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc25&_hsenc=p2ANqtz-_uQyaW_7pnqwQIW-3FoFS7_krfM3-VnZBU7hL0K69XIWaBHVi1-kqUzjO7bmawLxr2lo08ZTlvmHCuhnHEjdmfnUZ25Q&_hsmi=378460064&utm_content=378460064&utm_source=hs_email Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis Free to access with registration until Sept 9, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01562-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc25&_hsenc=p2ANqtz-83PGN1Ic3AGWEwP5hGDKuNTgPjVKPF5BC5gpEOY9KI7wHstEe8Dh-JXOq9OxDn1rPqwYYJlqDFRCEvZ0kycq3fxsmaXQ&_hsmi=378460064&utm_content=378460064&utm_source=hs_email Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial Free to access with registration until Sept 9, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01633-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esc25&_hsenc=p2ANqtz-8L8GHlUzWoANXdvqCd6tKASt5v1rmZuRwIgvAoZcpsbjaiQJMIcjtUAzsJheoGzfcekonfKLuGgQCv2q9ukEYgdDDfUw&_hsmi=378460064&utm_content=378460064&utm_source=hs_email